Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03609827 · ClinicalTrials.gov registry record
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
A clinical trial of Sickle Cell Disease and Hematologic Malignancies, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT03609827: Completed study of Sickle Cell Disease and Hematologic Malignancies, sponsored by University of California, San Francisco.
NCT03609827 is a study of Sickle Cell Disease and Hematologic Malignancies that has completed, run by University of California, San Francisco. The registered enrollment target is 25 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03609827, a study of Sickle Cell Disease and Hematologic Malignancies, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of melphalan in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that certain clinical and individual factors cause changes in melphalan drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.
Conditions Studied
Interventions
- DRUG Melphalan
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2021-05-31 |
What the finished NCT03609827 record still lists
NCT03609827 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower).
The record links to 8 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Melphalan is the first listed.
NCT03609827 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03609827 about?
NCT03609827 is a clinical study titled "Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients". Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of melphalan in their bodies and if drug levels are related to whether or not a child experiences severe side-effec...
What is the current status of trial NCT03609827?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2015-09-01. Estimated completion is 2021-05-31.
What conditions does trial NCT03609827 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Hematologic Malignancies, Thalassemia, Hemoglobinopathies, Immunodeficiencies.
What interventions are being tested in trial NCT03609827?
The interventions under investigation include: Melphalan (DRUG).
Who is sponsoring clinical trial NCT03609827?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03609827 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03609827's enrollment target sits among peer trials
25 153rd of 213 higher than 55 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI